CRIS Current Research Information System

ANDREONE, PIETRO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 20.652
AS - Asia 14.418
EU - Europa 10.825
SA - Sud America 935
AF - Africa 857
Continente sconosciuto - Info sul continente non disponibili 675
OC - Oceania 17
Totale 48.379
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 20.282
VN - Vietnam 4.186
SG - Singapore 3.985
CN - Cina 3.242
GB - Regno Unito 2.869
SE - Svezia 1.548
IT - Italia 1.452
DE - Germania 1.394
HK - Hong Kong 981
FR - Francia 734
IN - India 664
BR - Brasile 646
RU - Federazione Russa 596
UA - Ucraina 484
IE - Irlanda 425
NL - Olanda 294
ZA - Sudafrica 267
EE - Estonia 213
JP - Giappone 208
CI - Costa d'Avorio 200
KR - Corea 195
CA - Canada 193
BD - Bangladesh 192
TG - Togo 173
FI - Finlandia 150
CH - Svizzera 138
JO - Giordania 131
AR - Argentina 117
PH - Filippine 114
BG - Bulgaria 101
BE - Belgio 97
GR - Grecia 96
TH - Thailandia 87
SC - Seychelles 76
ID - Indonesia 69
MX - Messico 65
EC - Ecuador 62
PL - Polonia 52
TW - Taiwan 47
NG - Nigeria 45
IQ - Iraq 39
AT - Austria 37
CO - Colombia 37
TR - Turchia 37
SA - Arabia Saudita 36
IR - Iran 34
PK - Pakistan 30
UZ - Uzbekistan 29
ES - Italia 26
MY - Malesia 22
LB - Libano 21
CL - Cile 20
VE - Venezuela 19
AU - Australia 16
LT - Lituania 16
CR - Costa Rica 15
HN - Honduras 14
EG - Egitto 13
ET - Etiopia 12
JM - Giamaica 12
NI - Nicaragua 12
PE - Perù 12
PY - Paraguay 12
CZ - Repubblica Ceca 11
HR - Croazia 11
MA - Marocco 11
KE - Kenya 10
KZ - Kazakistan 10
RO - Romania 10
TN - Tunisia 10
PT - Portogallo 9
TT - Trinidad e Tobago 9
DZ - Algeria 8
GT - Guatemala 8
AE - Emirati Arabi Uniti 7
DK - Danimarca 7
DO - Repubblica Dominicana 7
HU - Ungheria 7
IL - Israele 7
NP - Nepal 7
PR - Porto Rico 7
RS - Serbia 7
AL - Albania 6
AZ - Azerbaigian 6
NO - Norvegia 6
PS - Palestinian Territory 6
MD - Moldavia 5
MK - Macedonia 5
PA - Panama 5
SV - El Salvador 5
SY - Repubblica araba siriana 5
A2 - ???statistics.table.value.countryCode.A2??? 4
BY - Bielorussia 4
CG - Congo 4
MM - Myanmar 4
SI - Slovenia 4
UY - Uruguay 4
AO - Angola 3
BB - Barbados 3
BO - Bolivia 3
Totale 47.636
Salva come PNG Salva come JPEG
Città #
Singapore 2.780
Southend 2.522
Ashburn 2.026
Fairfield 1.997
San Jose 1.303
Chandler 1.244
Houston 1.006
Woodbridge 954
Hong Kong 936
Seattle 890
Ho Chi Minh City 854
Wilmington 803
Hanoi 743
Dong Ket 740
Santa Clara 673
Cambridge 669
Ann Arbor 667
Princeton 630
Dublin 419
Boardman 416
Beijing 414
Hefei 402
Council Bluffs 354
Los Angeles 309
Dallas 300
Lauterbourg 286
Jacksonville 280
Westminster 270
Nanjing 256
Bologna 249
New York 229
Padova 219
Abidjan 200
Tokyo 186
Lomé 173
Berlin 152
Seoul 149
Chicago 141
Haiphong 135
Jinan 135
Buffalo 131
Amman 130
San Diego 128
Da Nang 126
Shenyang 120
São Paulo 117
Helsinki 116
Saint Petersburg 116
Bern 111
Frankfurt am Main 111
Milan 108
Sofia 97
Redondo Beach 94
Brussels 93
Munich 89
Changsha 84
Tianjin 82
Guangzhou 79
Florence 76
Phoenix 75
Nanchang 71
Hebei 67
Turin 67
Redmond 58
Bremen 57
Shanghai 57
Medford 55
Biên Hòa 54
Mülheim 53
Rome 50
Dearborn 49
Jiaxing 49
Des Moines 48
Montreal 48
London 47
Bengaluru 46
Falls Church 45
Norwalk 45
Orem 44
Hải Dương 43
Toronto 43
Yubileyny 43
Abeokuta 40
Hangzhou 39
San Francisco 39
Thái Nguyên 39
Zhengzhou 39
Johannesburg 38
Brooklyn 36
Ningbo 36
Wuhan 36
Falkenstein 35
Mahé 35
Bangkok 33
Can Tho 33
Quận Bình Thạnh 32
The Dalles 30
Washington 30
Amsterdam 28
Bắc Ninh 28
Totale 30.959
Salva come PNG Salva come JPEG
Nome #
G-CSF administration is not related to PEG-IFN alfa-213 treatment duration nor response in liver transplanted patients with HCV recurrence 528
Clinical trial: peg-interferon alfa-2b and ribavirin for the treatment of genotype-1 hepatitis C recurrence after liver transplantation 342
Adefovir and lamivudine combination therapy is superior to ADV monotherapy for lamivudine-resistant patients with HBeAG-negative chronic hepatitis B 307
Accuracy of elastography point quantification and steatosis influence on assessing liver fibrosis in patients with chronic hepatitis C 306
Point quantification elastography in the evaluation of liver elasticity in healthy volunteers: a reliability study based on operator expertise 291
Clinical Impact and Safety of Anticoagulants for Portal Vein Thrombosis in Cirrhosis 275
Working together to tackle HCV infection: Ombitasvir/paritaprevir/ritonavir and dasabuvir combination 274
Accuracy of VirtualTouch Acoustic Radiation Force Impulse (ARFI) imaging for the diagnosis of cirrhosis during liver ultrasonography 272
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 268
Genetic variability of hepatitis C virus in HBV/HCV co-infection and HCV single-infection. 267
Adaptive response in Hepatitis B virus infection 261
Clinical and serological profile of primary biliary cirrhosis in men. 258
ABT-450: A novel agent for the treatment of CHC genotype 1: Focus on treatment-experienced patients 255
Liver Stiffness measurments using Fibroscan after three months of IFN-based antiviral therapy is unlikely to predict viral response in cirrhotic patients. 254
G-CSF administration is not related to Peg-IFN alfa-2b treatment duration nor response in liver transplanted patients with HCV recurrence. 251
Cytokine profile of peripheral blood mononuclear cells from patients with different outcomes of hepatitis C virus infection. 246
Acquired intestinal lymphangiectasia successfully treated with a low fat and MCT-enriched diet in a patient with liver transplantation. 245
Anti-synthetase syndrome with lung involvement associated with primary biliary cirrhosis: A case report 241
A new prognostic model to predict drop-out from the waiting list in cirrhotic candidates for liver transplantation wirh MELD score <18. 236
Diagnostic Performance of PIVKA-II in Italian Patients with Hepatocellular Carcinoma 234
Vitamin E for the treatment of E-antigen-positive chronic hepatitis B in paediatric patients: results of a randomized phase 2 controlled study. 234
Hepatocellular carcinoma risk assessment by the measurement of liver stiffness variations in HCV cirrhotics treated with direct acting antivirals 232
Add-on peginterferon alfa-2a to nucleos(t)ide analogue therapy for Caucasian patients with hepatitis B ‘e’ antigen-negative chronic hepatitis B genotype D 231
Hepatitis C virus recurrence after liver transplantation: a 10-year evaluation. 229
Presence of Hepatocellular Carcinoma Does Not Affect Course and Response to Anticoagulation of Bland Portal Vein Thrombosis in Cirrhotic Patients 227
DAAs treatment in HCV recurrence after liver transplantation: Clinical usefulness of non-invasive methods 227
Immune inflammation indicators and ALBI score to predict liver cancer in HCV-patients treated with direct-acting antivirals 227
Criteria for diagnosing benign portal vein thrombosis in the assessment of patients with cirrhosis and hepatocellular carcinoma for liver transplantation. 226
Development of different psychiatric manifestations during antiviral therapy for chronic hepatitis C. 225
Prospective, observational real-life study on eligibility for and outcomes of antiviral treatment with peginterferon α plus ribavirin in chronic hepatitis C 225
Assessment of Radiofrequency Ablation Efficacy for Hepatocellular Carcinoma by Histology and Pre-transplant Radiology 221
Alcohol and viral hepatitis: a mini-review. 221
Low replication and variability of HBV pre-core in concomitant infection with hepatitis B and hepatitis C viruses 217
Safety and efficacy of once daily ledipasvir/sofosbuvir fixed-dose combination in patients with chronic hepatitis C 217
Direct acting antivirals for the treatment of elderly patients with HCV advanced disease in the real life practice 216
Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score 216
Allocation priority in non urgent liver transplantation: an overview of proposed scoring systems 216
Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation. 215
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data 215
Hepatitis B virus reactivation among hepatitis C patients treated with direct-acting antiviral therapies in routine clinical practice 215
Long term follow-up and outcome of liver transplantation for alcoholic liver disease: a single center case-control study 214
Assessment of liver fibrosis in trnsplant recipients with recurrent HCV infection: Usefulness of transient elastography. 214
Imbalance of Neutrophils and Lymphocyte Counts Can Be Predictive of Hepatocellular Carcinoma Occurrence in Hepatitis C-related Cirrhosis Treated With Direct-acting Antivirals 213
Impact of psychosocial status on liver transplant process 213
The use of obeticholic acid for the management of non-viral liver disease: current clinical practice and future perspectives 213
Hepatitis C Virus-related chronic liver disease in elderly patients: an Italian cross-sectional study. 212
Treatment with direct acting antiviral agents-based regimen in HCV patients with advanced liver disease: Analysis of an Italian multicenter observational study 212
Thymosin-alpha 1 plus interferon-alpha for naive patients with chronic hepatitis C: results of a randomized controlled pilot trial 211
Genetic heterogeneity of hepatitis C virus in HBV/HCV co-infection 210
Imaging features of microvascular invasion in hepatocellular carcinoma developed after direct-acting antiviral therapy in HCV-related cirrhosis 210
Serum hepatitis B surface antigen monitoring in long-term Lamivudine-treated hepatitis B virus patients 209
Vitamins in the treatment of chronic viral hepatitis. 209
Reinfusion of highly purified CD133+ bone marrow-derived stem/progenitor cells in patients with end-stage liver disease: a phase I clinical trial 208
Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis 207
Clinical Impact and behaviour of serum autoantibodies in adult liver transplantation 207
Comparison of IFN-alpha 2b with or without ribavirin for treatment of chronic hepatitis C in HIV-positive patients infected with hepatitis C virus genotype 3a 206
Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV 206
Secondary prophylaxis of hepatocellular carcinoma: the comparison of direct-acting antivirals with pegylated interferon and untreated cohort 205
Monitoring the treatment of hepatitis C with directly acting antivirals by serological and molecular methods 205
Virological analysis, genotypes and mutational patterns of the HBV pre-core/core gene in HBV/HCV-related hepatocellular carcinoma. 204
Grazoprevir/elbasvir fixed-dose combination for hepatitis C 204
Calcineurin inhibitors levels reduction during treatment with Sofosbuvir in liver transplanted patients. 203
Pegylated interferon plus ribavirin for recurrent Hepatitis C infection after liver transplantation in naive and non-responder patients on a stable immunosuppressive regimen. 202
Alcoholic liver disease: pathophisiological aspects and risk factors. A review. 202
Virus-specific immune response in HBeAg-negative chronic hepatitis B: relationship with clinical profile and HBsAg serum levels. 202
A Case of Acute Liver Failure during Ritonavir-Boosted Paritaprevir, Ombitasvir and Dasabuvir Therapy in a Patient with HCV Genotype 1b Cirrhosis 202
A new approach to the use of α-fetoprotein as surveillance test for hepatocellular carcinoma in patients with cirrhosis. 201
Alopecia universalis after discontinuation of pegylated interferon and ribavirin combination therapy for hepatitis C: a case report. 200
An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs 199
Characterization of a stereotypical cellular and extracellular adult liver progenitor cell niche in rodents and diseased human liver 198
DAAs treatment in hepatitis C virus recurrence after Liver Transplantation: clinical usefulness of non-invasive methods 198
Transient elastography in healthy subjects and factors influencing liver stiffness in non-alcoholi fatty liver disease: an Italian community-based population study. 197
Surveillance for hepatocellular carcinoma in elderly italian patients with cirrhosis. Effects on cancer staging and patients survival. 197
Quality of life in liver transplant recipients during the Corona virus disease 19 pandemic: A multicentre study 195
Liver stiffness and serum fibrosis biomarker variations after DAAs treatment: Predictive role in HCC development in cirrhotic patients 195
Gamma-hydroxybutyric acid plus naltrexone in the treatment of alcoholics resistant to monotherapy. 194
Impact of etiology of cirrhosis on the survival of patients diagnosed with hepatocellular carcinoma during surveillance. 194
Serum hepatitis B core-related antigen is an effective tool to categorize patients with HBeAg-negative chronic hepatitis B 193
In portal hypertensive cirrhotic patients abdominal porto-systemic collaterals at ultrasound identify a group of patients at high risk of death 193
Vitamin E for the treatment of children with hepatitis B e antigen-positive chronic hepatitis: A systematic review and meta-analysis 192
Liver transplantation for patients with alcoholic liver disease: an open question 191
Chronic hepatitis B: Are we close to a cure? 191
DIAGNOSTIC ACCURACY OF LIVER AND SPLEEN STIFFNESS MEASUREMENT FOR PORTAL HYPERTENSION USING BIDIMENSIONAL SHEAR WEAVE ELASTOGRAPHY 191
Molecular and functional characterization of CD133+stem/progenitor cells infused in patients with end-stage liver disease reveals their interplay with stromal liver cells 191
Stem cell mobilization and collection in patients with liver cirrhosis. 190
Prognostic value of a single HVPG measurement and Doppler-ultrasound evaluation in patients with cirrhosis and portal hypertension 190
Primary prophylaxis with nadolol in cirrhotic patients: Doppler patterns of splanchnic hemodynamics in good and poor responders. 189
Deregulation of microRNA expression in peripheral blood mononuclear cells from patients with HCV-related malignancies 189
Nivolumab-induced cholangitic liver disease: A novel form of serious liver injury 189
Antibodies against pegylated interferon-alpha affect response to treatment in patients with chronic hepatitis C. 189
An in-depth psychosocial and biochemical evaluation in transplant recipients for alcoholic liver disease should be planned. 188
Treating hepatitis C in the elderly: the future is near? 188
Bipolar and related disorders induced by sodium 4-phenylbutyrate in a male adolescent with bile salt export pump deficiency disease 188
High incidence of allograft dysfunction in liver transplant patients treated with PEG-Interferon alfa-2b and Ribavirin for hepatitis C recurrence: possible de novo autoimmune hepatitis? 187
A New Two-Dimensional Shear Wave Elastography for Noninvasive Assessment of Liver Fibrosis in Healthy Subjects and in Patients with Chronic Liver Disease - Eine neue zweidimensionale Shear-Wave-Elastografie zur nicht-invasiven Beurteilung der Leberfibrose bei Gesunden und bei Patienten mit chronischer Lebererkrankung 186
The increase of Ribavirin dose improves sustained virological response in HCV-Genotype 1 patients with a partial response to PEG-Interferon and Ribavirin. 186
In vitro effect of thymosin-alpha1 and interferon-alpha on Th1 and Th2 cytokine synthesis in patients with eAg-negative chronic hepatitis B. 185
Spleen Stiffness Measurements Predict the Risk of Hepatic Decompensation after Direct-Acting Antivirals in HCV Cirrhotic Patients 185
Modeling cost-effectiveness and health gains of a “universal” versus “prioritized” hepatitis C virus treatment policy in a real-life cohort 184
Hepatitis B virus and immune response. 183
Totale 21.972
Salva come PNG Salva come JPEG
Categoria #
all - tutte 133.758
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 133.758
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20224.294 0 0 0 460 465 305 90 343 193 373 1.216 849
2022/20235.255 617 799 275 716 296 399 154 260 910 153 415 261
2023/20241.252 95 239 111 111 109 243 55 110 39 63 36 41
2024/20255.472 162 935 411 491 876 284 283 131 69 352 201 1.277
2025/202614.339 1.539 1.089 1.371 1.036 1.594 789 1.340 744 2.817 975 553 492
2026/20272.638 302 440 1.016 880 0 0 0 0 0 0 0 0
Totale 48.379